Glucocorticoid Receptor Signaling in NSCLC: Mechanistic Aspects and Therapeutic Perspectives

Recent advances in non-small cell lung cancer (NSCLC) biology and the discovery of novel therapeutic targets have led to the development of new pharmacological agents that may improve the clinical outcome of patients with NSCLC. The glucocorticoid receptor (GR) is an evolutionarily conserved protein...

Full description

Saved in:
Bibliographic Details
Published in:Biomolecules (Basel, Switzerland) Switzerland), 2023-08, Vol.13 (9), p.1286
Main Authors: Papavassiliou, Kostas A, Anagnostopoulos, Nektarios, Papavassiliou, Athanasios G
Format: Article
Language:English
Subjects:
Biology
Brain cancer
Breast cancer
Care and treatment
Cell cycle
Cellular signal transduction
Chemotherapy
Corticosteroids
Cyclin-dependent kinases
Development and progression
Drug development
Genes
glucocorticoid receptor
Glucocorticoid receptors
Glucocorticoids
Health aspects
Immune checkpoint inhibitors
Immunosuppressive agents
Kinases
Ligands
Lung cancer
Lung cancer, Non-small cell
Medical prognosis
Molecular modelling
non-small cell lung cancer
Non-small cell lung carcinoma
Opinion
Patients
Phosphorylation
Prostate
Protein expression
Proteins
Small cell lung carcinoma
Therapeutic targets
Transcription factors
Tumorigenesis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recent advances in non-small cell lung cancer (NSCLC) biology and the discovery of novel therapeutic targets have led to the development of new pharmacological agents that may improve the clinical outcome of patients with NSCLC. The glucocorticoid receptor (GR) is an evolutionarily conserved protein belonging to the nuclear receptor superfamily of transcription factors and mediates the diverse actions of glucocorticoids in cells. Data suggest that the GR may play a relevant role in the molecular mechanisms of NSCLC tumorigenesis and malignant progression. Additionally, evidence indicates that glucocorticoids may affect the efficacy of standard treatment, including chemotherapy, immune checkpoint inhibitors, and targeted therapy. Furthermore, several findings show that GR expression may probably be associated with NSCLC patient survival. Finally, glucocorticoids may be used as therapeutic agents for the clinical management of NSCLC patients. Here, we briefly review the latest advances on the biological role of GR signaling in NSCLC and discuss the potential use of the GR as a prognostic and predictive biomarker. Importantly, we explore the therapeutic potential of glucocorticoids and the effect of adding such drugs to standard therapies for NSCLC.
ISSN:2218-273X
2218-273X
DOI:10.3390/biom13091286